Increased blood mRNA expression of inflammatory and anti-fibrotic markers in dogs with congestive heart failure

Research in Veterinary Science

Volumn 93, Issue 2, 2012, Pages 879-885

  Fonfara, S ^a   Tew, S R ^a   Cripps, P ^a   Dukes McEwan, J ^a   Clegg, P D ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Cytokine; Heart failure; Interleukin; Matrix metalloproteinase; TIMP

Indexed keywords

BENAZEPRIL; FUROSEMIDE; GAMMA INTERFERON; GELATINASE A; GELATINASE B; GLYCERYL TRINITRATE; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; INTERSTITIAL COLLAGENASE; MESSENGER RNA; MOLECULAR MARKER; PIMOBENDAN; SPIRONOLACTONE; STROMELYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TISSUE INHIBITOR OF METALLOPROTEINASE 4; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2; TRANSFORMING GROWTH FACTOR BETA3; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DOG; FEMALE; FIBROSIS; GENE EXPRESSION; HEART VENTRICLE REMODELING; INFLAMMATION; MALE; NONHUMAN; POLYMERASE CHAIN REACTION;

ANIMALS; BIOLOGICAL MARKERS; CLUSTER ANALYSIS; DOG DISEASES; DOGS; FEMALE; GENE EXPRESSION REGULATION; HEART FAILURE; INFLAMMATION; MALE; RNA, MESSENGER;

CANIS FAMILIARIS;

EID: 84863113536     PISSN: 00345288     EISSN: 15322661     Source Type: Journal    
DOI: 10.1016/j.rvsc.2011.10.020     Document Type: Article

References (51)

1. Aharinejad S., Krenn K., Paulus P., Schafer R., Zuckermann A., Grimm M., Abraham D. Differential role of TGF-beta1/bFGF and ET-1 in graft fibrosis in heart failure patients. American Journal of Transplantation 2005, 5:2185-2192.
2. Anker S.D., von Haehling S. Inflammatory mediators in chronic heart failure: an overview. Heart 2004, 90:464-470.
3. Aupperle H., Marz I., Thielebein J., Schoon H.A. Expression of transforming growth factor-beta1, -beta2 and -beta3 in normal and diseased canine mitral valves. Journal of Comparative Pathology 2008, 139:97-107.
4. Aupperle H., Thielebein J., Kiefer B., Marz I., Dinges G., Schoon H.A. An immunohistochemical study of the role of matrix metalloproteinases and their tissue inhibitors in chronic mitral valvular disease (valvular endocardiosis) in dogs. Veterinary Journal 2009, 180:88-94.
5. Bradham W.S., Moe G., Wendt K.A., Scott A.A., Konig A., Romanova M., Naik G., Spinale F.G. TNF-alpha and myocardial matrix metalloproteinases in heart failure: relationship to LV remodeling. American Journal of Physiology. Heart and Circulatory Physiology 2002, 282:H1288-H1295.
6. Bujak M., Frangogiannis N.G. The role of IL-1 in the pathogenesis of heart disease. Archivum Immunologiae at Therapiae Experimentalis (Warsz) 2009, 57:165-176.
7. Castellano G., Affuso F., Di Conza P., Fazio S. Myocarditis and dilated cardiomyopathy: possible connections and treatments. Journal of Cardiovascular Medicine (Hagerstown) 2008, 9:666-671.
8. Chen D., Assad-Kottner C., Orrego C., Torre-Amione G. Cytokines and acute heart failure. Critical Care Medicine 2008, 36:S9-S16.
9. Clements D.N., Carter S.D., Innes J.F., Ollier W.E., Day P.J. Analysis of normal and osteoarthritic canine cartilage mRNA expression by quantitative polymerase chain reaction. Arthritis Research and Therapy 2006, 8:R158.
10. Clements D.N., Fitzpatrick N., Carter S.D., Day P.J. Cartilage gene expression correlates with radiographic severity of canine elbow osteoarthritis. Veterinary Journal 2009, 179:211-218.
11. Creemers E.E., Pinto Y.M. Molecular mechanisms that control interstitial fibrosis in the pressure-overloaded heart. Cardiovascular Research 2011, 89:265-272.
12. Creemers E.E., Cleutjens J.P., Smits J.F., Daemen M.J. Matrix metalloproteinase inhibition after myocardial infarction: a new approach to prevent heart failure?. Circulation Research 2001, 89:201-210.
13. Creemers E.E., Davis J.N., Parkhurst A.M., Leenders P., Dowdy K.B., Hapke E., Hauet A.M., Escobar P.G., Cleutjens J.P., Smits J.F., Daemen M.J., Zile M.R., Spinale F.G. Deficiency of TIMP-1 exacerbates LV remodeling after myocardial infarction in mice. American Journal of Physiology. Heart and Circulatory Physiology 2003, 284:H364-H371.
14. Deschamps A.M., Spinale F.G. Pathways of matrix metalloproteinase induction in heart failure: bioactive molecules and transcriptional regulation. Cardiovascular Research 2006, 69:666-676.
15. Falk T., Jönsson L., Olsen L.H., Pedersen H.D. Arteriosclerotic changes in the myocardium, lung, and kidney in dogs with chronic congestive heart failure and myxomatous valve disease. Cardiovascular Pathology 2006, 15:185-193.
16. Fedak P.W.M., Smookler D.S., Kassiri Z., Ohno N., Leco K.J., Verma S., Mickle D.A.G., Watson K.L., Hojilla C.V., Cruz W., Weisel R.D., Li R.-K., Khokha R. TIMP-3 deficiency leads to dilated cardiomyophathy. Circulation 2004, 110:2401-2409.
17. Fonfara, S., Hetzel, U., Tew, S.R., Dukes-McEwan, J., Cripps, P., Clegg, P., 2011. Leptin expression in dogs with cardiac disease and congestive heart failure. Journal of Veterinary Internal Medicine, doi: 10.1111/j.1939-1676.2011.00782.x.
18. Garvican E.R., Vaughan-Thomas A., Redmond C., Clegg P.D. Chondrocytes harvested from osteochondritis dissecans cartilage are able to undergo limited in vitro chondrogenesis despite having perturbations of cell phenotype in vivo. Journal of Orthopaedic Research 2008, 26:1133-1140.
19. German A.J., Ryan V.H., German A.C., Wood I.S., Trayhurn P. Obesity, its associated disorders and the role of inflammatory adipokines in companion animals. Veterinary Journal 2010, 185:4-9.
20. Gilbert S.J., Wotton P.R., Tarlton J.F., Duance V.C., Bailey A.J. Increased expression of promatrix metalloproteinase-9 and neutrophil elastase in canine dilated cardiomyopathy. Cardiovascular Research 1997, 34:377-383.
21. Givvimani S., Tyagi N., Sen U., Mishra P.K., Qipshidze N., Munjal C., Vacek J.C., Abe O.A., Tyagi S.C. MMP-2/TIMP-2/TIMP-4 versus MMP-9/TIMP-3 in transition from compensatory hypertrophy and angiogenesis to decompensatory heart failure. Archives of Physiology and Biochemistry 2010, 116:63-72.
22. Graham H.K., Horn M., Trafford A.W. Extracellular matrix profiles in the progression to heart failure. European young physiologists symposium keynote lecture-bratislava 2007. Acta Physiologica (Oxford) 2008, 194:3-21.
23. Hedayat M., Mahmoudi M.J., Rose N.R., Rezaei N. Proinflammatory cytokines in heart failure: double-edged swords. Heart Failure Reviews 2010, 15:543-562.
24. Henriksen P.A., Newby D.E. Therapeutic inhibition of tumour necrosis factor alpha in patients with heart failure: cooling an inflamed heart. Heart 2003, 89:14-18.
25. Kassiri Z., Oudit G.Y., Sanchez O., Dawood F., Mohammed F.F., Nuttall R.K., Edwards D.R., Liu P.P., Backx P.H., Khokha R. Combination of tumor necrosis factor-alpha ablation and matrix metalloproteinase inhibition prevents heart failure after pressure overload in tissue inhibitor of metalloproteinase-3 knock-out mice. Circulation Research 2005, 97:380-390.
26. Kaur K., Dhingra S., Slezak J., Sharma A.K., Bajaj A., Singal P.K. Biology of TNFalpha and IL-10, and their imbalance in heart failure. Heart Failure Reviews 2009, 14:113-123.
27. Keene B.W., Bonagura J.D. Management of heart failure in dogs. Current Veterinary Therapy XIV 2009, 769-780. Sounders Elsevier, St Louis. J.D. Bonagura, D.C. Twedt (Eds.).
28. Khan A., Moe G.W., Nili N., Rezaei E., Eskandarian M., Butany J., Strauss B.H. The cardiac atria are chambers of active remodeling and dynamic collagen turnover during evolving heart failure. Journal American College of Cardiology 2004, 43:68-76.
29. Koch M., Savvatis K., Scheeler M., Dhayat S., Bonaventura K., Pohl T., Riad A., Bulfone-Paus S., Schultheiss H.P., Tschope C. Immunosuppression with an interleukin-2 fusion protein leads to improved LV function in experimental ischemic cardiomyopathy. International Immunopharmacology 2010, 10:207-212.
30. Lim H., Zhu Y.Z. Role of transforming growth factor-beta in the progression of heart failure. Cellular and Molecular Life Science 2006, 63:2584-2596.
31. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001, 25:402-408.
32. Ljungvall I., Rajamaki M.M., Crosara S., Olsen L.H., Kvart C., Borgarelli M., Hoglund K., Haggstrom J. Evaluation of plasma activity of matrix metalloproteinase-2 and -9 in dogs with myxomatous mitral valve disease. American Journal of Veterinary Research 2011, 72:1022-1028.
33. Lopez B., Gonzalez A., Diez J. Circulating biomarkers of collagen metabolism in cardiac diseases. Circulation 2010, 121:1645-1654.
34. Mann D.L. Recent insights into the role of tumor necrosis factor in the failing heart. Heart Failure Reviews 2001, 6:71-80.
35. Matsumoto M., Tsujino T., Lee-Kawabata M., Naito Y., Sakoda T., Ohyanagi M., Masuyama T. Serum interleukin-6 and C-reactive protein are markedly elevated in acute decompensated heart failure patients with left ventricular systolic dysfunction. Cytokine 2010, 49:264-268.
36. Meurs K.M., Fox P.R., Miller M.W., Kapadia S., Mann D.L. Plasma concentrations of tumor necrosis factor-alpha in cats with congestive heart failure. American Journal of Veterinary Research 2002, 63:640-642.
37. Obayashi K., Miyagawa-Tomita S., Matsumoto H., Koyama H., Nakanishi T., Hirose H. Effects of transforming growth factor-beta3 and matrix metalloproteinase-3 on the pathogenesis of chronic mitral valvular disease in dogs. American Journal of Veterinary Research 2011, 72:194-202.
38. Oyama M.A., Chittur S.V. Genomic expression patterns of mitral valve tissues from dogs with degenerative mitral valve disease. American Journal of Veterinary Research 2006, 67:1307-1318.
39. Porter K.E., Turner N.A. Cardiac fibroblasts: at the heart of myocardial remodeling. Pharmacology and Therapeutics 2009, 123:255-278.
40. Sharma R., Fu S.M., Ju S.T. IL-2: a two-faced master regulator of autoimmunity. Journal of Autoimmunity 2011.
41. Siwik D.A., Colucci W.S. Regulation of matrix metalloproteinases by cytokines and reactive oxygen/nitrogen species in the myocardium. Heart Failure Reviews 2004, 9:43-51.
42. Spinale F.G. Matrix metalloproteinases: regulation and dysregulation in the failing heart. Circulation Research 2002, 90:520-530.
43. Spinale F.G. Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function. Physiological Reviews 2007, 87:1285-1342.
44. Strickland K.N. Pathophysiology and therapy of heart failure. Manual of Canine and Feline Cardiology 2008, 288-314. Saunders Elsevier, St Louis. fourth ed. L.P. Tilley, F.W.K. Smith, M.A. Oyama, M.M. Sleeper (Eds.).
45. Tamariz L., Hare J.M. Inflammatory cytokines in heart failure: roles in aetiology and utility as biomarkers. European Heart Journal 2010, 31:768-770.
46. Tatli E., Kurum T. A controlled study of the effects of carvedilol on clinical events, left ventricular function and proinflammatory cytokines levels in patients with dilated cardiomyopathy. The Canadian Journal of Cardiology 2005, 21:344-348.
47. van den Borne S.W., Diez J., Blankesteijn W.M., Verjans J., Hofstra L., Narula J. Myocardial remodeling after infarction: the role of myofibroblasts. Nature Review Cardiology 2010, 7:30-37.
48. Vanderheyden M., Paulus W.J., Voss M., Knuefermann P., Sivasubramanian N., Mann D., Baumgarten G. Myocardial cytokine gene expression is higher in aortic stenosis than in idiopathic dilated cardiomyopathy. Heart 2005, 91:926-931.
49. Vanhoutte D., Heymans S. TIMPs and cardiac remodeling: 'embracing the MMP-independent-side of the family'. Journal of molecular and cellular cardiology 2010, 48:445-453.
50. von Haehling S., Schefold J.C., Lainscak M., Doehner W., Anker S.D. Inflammatory biomarkers in heart failure revisited: much more than innocent bystanders. Heart Failure Clinics 2009, 5:549-560.
51. Yndestad A., Holm A.M., Muller F., Simonsen S., Froland S.S., Gullestad L., Aukrust P. Enhanced expression of inflammatory cytokines and activation markers in T-cells from patients with chronic heart failure. Cardiovascular Research 2003, 60:141-146.